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Background: Epithelial-mesenchymal transition (EMT) is a process implicated in cancer metastasis that involves the
conversion of epithelial cells to a more mesenchymal and invasive cell phenotype. In breast cancer cells EMT is
associated with altered store-operated calcium influx and changes in calcium signalling mediated by activation of
cell surface purinergic receptors. In this study, we investigated whether MDA-MB-468 breast cancer cells induced to
undergo EMT exhibit changes in mRNA levels of calcium channels, pumps and exchangers located on intracellular
calcium storing organelles, including the Golgi, mitochondria and endoplasmic reticulum (ER).
Methods: Epidermal growth factor (EGF) was used to induce EMT in MDA-MB-468 breast cancer cells. Serum-deprived
cells were treated with EGF (50 ng/mL) for 12 h and gene expression was assessed using quantitative RT-PCR.
Results and conclusions: These data reveal no significant alterations in mRNA levels of the Golgi calcium pump
secretory pathway calcium ATPases (SPCA1 and SPCA2), or the mitochondrial calcium uniporter (MCU) or Na+/Ca2+
exchanger (NCLX). However, EGF-induced EMT was associated with significant alterations in mRNA levels of specific ER
calcium channels and pumps, including (sarco)-endoplasmic reticulum calcium ATPases (SERCAs), and inositol
1,4,5-trisphosphate receptor (IP3R) and ryanodine receptor (RYR) calcium channel isoforms. The most prominent change
in gene expression between the epithelial and mesenchymal-like states was RYR2, which was enriched 45-fold in
EGF-treated MDA-MB-468 cells. These findings indicate that EGF-induced EMT in breast cancer cells may be associated
with major alterations in ER calcium homeostasis.
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EMT facilitates cancer cell invasion and metastasis for-
mation, and has also been linked to the acquisition of a
stem cell-like phenotype, anchorage-independent growth
and chemoresistance in cancer cell lines and clinical
samples [1–4]. The phenotypic changes associated with
EGF-induced EMT are well characterised in the human* Correspondence: gregm@uq.edu.au
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reproduction in any medium, provided the orbreast cancer cell line MDA-MB-468, and include
changes in cell morphology; increased expression of the
transcription factor Twist and the intermediate filament
protein vimentin; and reduced E-cadherin expression
following chronic EGF treatment [5–8]. In addition,
EGF-induced EMT in MDA-MB-468 breast cancer cells
has been linked to altered plasma membrane calcium in-
flux [6,7,9].
Increases in cytosolic calcium may occur via calcium
entry through calcium permeable plasma membrane
channels, including transient receptor potential (TRP),td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or due to the release of calcium from internal stores
[10–12]. Calcium signals arising via influx or store-
release have distinct spatiotemporal profiles, modes of
activation, and cellular responses [13]. These two pro-
cesses often occur in parallel, for example calcium store
release triggering store-operated calcium influx [14], and
calcium influx via specific plasma membrane calcium
channels potentially causing calcium release from the ER
via calcium-induced calcium release (CICR) [15]. Mito-
chondrial calcium buffering may also alter the nature of
cytosolic calcium responses [16–19]. Thus changes in
the expression of calcium channels, pumps and ex-
changers located on intracellular calcium storing organ-
elles may alter the nature of the cytosolic calcium
response to a range of stimuli. However, while altered
store-operated [6,9] and non-stimulated [6] plasmalem-
mal calcium influx have been linked to the acquisition of
a more mesenchymal phenotype in breast cancer cells,
changes in calcium channels, pumps and exchangers lo-
cated on intracellular calcium storing organelles have
not been assessed during this process.
A phenotypic conversion and cellular heterogeneity
comparable to EMT, which is associated with a remo-
delling of intracellular calcium homeostasis, is observed
in vascular smooth muscle cells [20]. In response to cues
from the microenvironment, vascular smooth muscle
cells can switch from a contractile to a synthetic (pro-
liferative) phenotype [20]. Vascular smooth muscle cell
switching is associated with changes in the expression
of ER calcium channels and pumps, including reduced
expression of RYR3 and SERCA2a [20,21]. Vascular
smooth muscle cells are therefore one example of howFigure 1 EGF-induced EMT in MDA-MB-468 breast cancer cells. MDA-M
(50 ng/mL) as indicated to induce EMT. A) Twist and B) vimentin mRNA ex
following EGF treatment. Bar graphs show mean ± S.D. for nine individual
time point was assessed using two-way ANOVA with Bonferroni’s multipleintracellular calcium channels and pumps may be re-
modelled to meet the cellular requirements of specific
phenotypes.
In this study we assessed whether alterations in mRNA
levels of Golgi, mitochondrial and ER calcium channels,
pumps and exchangers were associated with EGF-induced
EMT in MDA-MB-468 breast cancer cells.
Results and discussion
EGF-induced EMT in MDA-MB-468 cells
MDA-MB-468 breast cancer cells treated with EGF (50
ng/mL) for 3, 6 or 12 h showed a significant increase in
mRNA levels of Twist (Figure 1A), a nuclear transcrip-
tion factor and marker of EMT [22]. This early EMT
event was followed by an increase in vimentin mRNA at
12 h post-EGF treatment (Figure 1B). These findings
were consistent with previous studies using this model
of EGF-induced EMT [5–8]. We assessed gene expres-
sion of calcium channels, pumps and exchangers located
on the Golgi, mitochondria and ER with EMT after
treatment with EGF for 12 h.
Golgi: SPCA1 and SPCA2
SPCAs are regulators of Golgi luminal calcium levels
[23]. Recently, we showed that SPCA1 is enriched in
basal-like breast cancers, a class of aggressive breast
cancers with EMT-like features [24]. Given the potential
for SPCAs to regulate processes important for carcino-
genesis [24,25] and the observed repositioning of the
Golgi, in some cell types, to the leading edge during cell
migration [26], we hypothesised that altered Golgi cal-
cium homeostasis may be a feature of EGF-induced
EMT. However, no significant alterations in the levels ofB-468 breast cancer cells were serum starved and treated with EGF
pression were assessed using real time RT-PCR at 3, 6 and 12 h
wells from three independent experiments. The effect of EGF at each
comparisons post-tests. * P < 0.05.
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(Figure 2B) were associated with EGF-induced EMT in
MDA-MB-468 breast cancer cells.
Mitochondria: MCU and NCLX
Excess mitochondrial calcium accumulation is a trigger
for cell death [27]. Downregulation of the MCU in HeLa
cervical cancer cells by miR-25 protects cells from
calcium-dependent apoptosis, and reduced expression of
MCU is a feature of poorly differentiated colonic adeno-
carcinomas [28]. In contrast, MCU expression appears
to be enriched in some breast cancer subtypes associatedFigure 2 Assessment of Golgi and mitochondrial calcium
transporters with EGF-induced EMT. Gene expression of A)
SPCA1, B) SPCA2, C) MCU and D) NCLX with EGF-induced EMT was
assessed using real-time RT-PCR. Bar graphs show mean ± S.D. for
nine individual wells from three independent experiments. Statistical
analysis was performed using an unpaired t-test.with a poor clinical prognosis [29]. Although several
studies have reported that EMT or expression of EMT-
associated transcription factors is associated with apop-
tosis resistance [30–32], the mechanism underpinning
this process has not been characterised. We evaluated
changes in gene expression of two key mitochondrial
calcium accumulation and release proteins—the MCU
[33,34] and NCLX [35]—in breast cancer cells induced
to undergo EMT with EGF. Our results show no
significant changes in the expression of the MCU or
NCLX with EGF-induced EMT in MDA-MB-468 cells
(Figure 2C & D). These findings indicate that if EGF-
induced EMT in breast cancer cells is associated with
apoptosis-resistance, it is not due to altered gene expres-
sion of the MCU or NCLX, at least under these study
conditions.
Endoplasmic reticulum: SERCAs, IP3Rs and RYRs
The ER is a major source of releasable calcium in epithe-
lial cells [36]. Luminal ER calcium levels are maintained
by SERCA calcium pumps, which are encoded by three
genes (ATP2A/SERCA1-3) [37]. Activation of phospho-
lipase C-coupled receptors (e.g., some G-protein coupled
receptors) leads to the production of IP3 and subsequent
activation of the ER calcium-permeable channels IP3R1,
IP3R2 and IP3R3 [38]. The nature of the cytosolic cal-
cium signal evoked by IP3 is highly dependent on the ex-
pression profile of IP3Rs [39]. For example, in B cells,
activation of IP3R2 produces regular and sustained cal-
cium oscillations, while IP3R3 generates a calcium re-
sponse that is characterised by a transient cytosolic
calcium peak and few oscillatory spikes [39]. IP3R sub-
types also differ in their sensitivity to IP3 [39]. To assess
possible alterations in ER calcium handling, we assessed
both SERCA and IP3R isoform mRNA levels in MDA-
MB-468 breast cancer cells induced to undergo EMT.
No significant change in SERCA1 gene expression was
observed (Figure 3A). However, an increase in SERCA2
and a down-regulation of SERCA3 was associated with
EGF-induced EMT (Figure 3B & C). EGF-induced EMT
was also associated with a 2.5-fold increase in IP3R1 and
a 2.2-fold increase in IP3R3 mRNA levels (Figure 3 D-F).
Changes in gene expression of SERCA2, SERCA3, IP3R1
and IP3R3 suggest that alterations in ER calcium homeo-
stasis may be a characterising feature of EGF-induced
EMT in MDA-MB-468 breast cancer cells.
To determine whether alterations in ER calcium
signalling with EMT could also be mediated via alter-
ations in the ryanodine receptor family of (sarco)-endo-
plasmic reticulum calcium release channels, mRNA levels
of ryanodine receptor isoforms were assessed during EGF-
induced EMT. There are three ryanodine receptor
isoforms in humans; RYR1 is predominantly expressed
skeletal muscle; RYR2 is the abundant isoform in cardiac
Figure 3 Assessment of ER calcium channels and pumps with EGF-induced EMT. Gene expression of A) SERCA1, B) SERCA2, C) SERCA3, D)
IP3R1, (E) IP3R2, (F) IP3R3, and (G) RYR2 was assessed using real-time RT-PCR. Bar graphs show mean ± S.D. for nine individual wells from three
independent experiments. * P < 0.05, unpaired t-test.
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cluding the brain [40]. RYR1 and RYR3 were not detected
in MDA-MB-468 epithelial breast cancer cells and expres-
sion of these isoforms was not induced to detectable levels
with EGF-induced EMT (data not shown). Levels of
mRNA for the RYR2 subtype were low in MDA-MB-468
breast cancer cells prior to EMT induction with EGF.
However, EGF-treatment induced a marked (46-fold)
increase in levels of RYR2 mRNA (Figure 3G). We were
unable to detect RYR2 expression in MDA-MB-468 breast
cancer cells with immunoblotting using a commercially
available antibody (Abcam C3-33, data not shown); how-
ever, corresponding to the increase in RYR2 gene expres-
sion, MDA-MB-468 breast cancer cells with a more
mesenchymal phenotype exhibited a modest but signifi-
cantly greater response to the ryanodine receptor activator
caffeine, as assessed through caffeine-mediated increases
in [Ca2+]CYT (Figure 4A & B).
Conclusions
Alterations in the expression of ER calcium channels
and pumps occur in cancer cell lines and clinicalcancer samples [12,41–45]. For example, expression of
SERCA3 is significantly reduced in colon carcinomas
and colon cancer cell lines compared to normal colonic
epithelia [41], and SERCA3 expression is elevated with
chemically-induced differentiation of colon, gastric and
lung cancer cell lines [41,42]. Therefore, the reduced
SERCA3 mRNA levels observed in this study with
EGF-induced EMT may reflect a loss of cellular dif-
ferentiation congruent with the acquisition of a more
stem cell-like phenotype. Future studies are needed to
assess whether these changes are related to EMT-
associated stemness and to assess the various SERCA
transcript variants with EGF-induced EMT. Ryanodine
receptor expression, using an antibody that detects
all ryanodine receptor isoforms, also correlates with
breast cancer tumour grade [43]. Furthermore, the in-
duction of RYR2 expression by factors/conditions
known to induce EMT in a variety of cell types (includ-
ing EGF, TGFβ [46] and hypoxia [47]), suggests that
RYR2 may be a key calcium channel for the mesenchy-
mal cell phenotype. The association between RYR2 and
EMT requires further investigation.
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Figure 4 Cytosolic calcium response to caffeine. Assessment of cytosolic calcium responses to 10 mM caffeine in MDA-MB-468 breast cells
induced to undergo EMT with EGF (24 h). A) Average response over baseline and B) peak response over baseline. Bar graph shows mean ± S.D
for nine individual wells from three independent experiments. * P < 0.05, unpaired t-test.
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ally required for EMT induction in breast cancer cells [48]
and that, in addition to regulating the conversion to a
more mesenchymal cell phenotype, EMT is associated
with a remodelling of non-stimulated, agonist-stimulated
and store-operated calcium influx [6,7]. This study
assessed changes in mRNA levels of intracellular calcium
channels, pumps and exchangers with EMT. Our results
demonstrate that similar to vascular smooth muscle cell
phenotypic switching [20], EMT in breast cancer cells is
associated with changes in gene expression of specific ER
calcium channels and pumps, the consequence of which
may be altered ER calcium storage and signalling. This is
in agreement with our previously published data showing
altered ER calcium release kinetics with EGF-induced
EMT in this cell line [6]. Changes in ER calcium handling
may lead to altered responses to phospholipase-C-coupled
receptor agonists, and may be important for the invasive
properties of mesenchymal-like cancer cells.
Materials and methods
Cell culture
MDA-MB-468 cells were maintained in Dulbecco’s Modi-
fied Eagle’s Medium (D6546, Sigma Aldrich) supplemented
with penicillin (100 U/mL, Invitrogen), streptomycin (100
μg/mL, Invitrogen), fetal bovine serum (10%, Sigma Al-
drich) and L-glutamine (4 mM, Invitrogen) [6]. To induce
EMT, MDA-MB-468 cells were serum-starved (0.5% fetal
bovine serum) for 24 h and stimulated with EGF (50 ng/
mL, Sigma Aldrich) for 12 h (gene expression) or 24 h(calcium assays) [5–7]. These time points were chosen be-
cause changes in mRNA levels are expected to precede
changes in functional responses. MDA-MB-468 cells were
maintained in a humidified incubator at 37°C with 5% CO2
and routinely tested negative for mycoplasma infection
(MycoAlert, Lonza). Short tandem repeat (STR) profiling
of the MDA-MB-468 cell line was performed by the
Queensland Institute of Medical Research using the
StemElite ID Profiling Kit (Promega).
RNA isolation and real-time RT-PCR
Total RNA was isolated and purified using the RNeasy
Plus Mini Kit (Qiagen). RNA (1000 ng) was reverse tran-
scribed using the Omniscript RT Kit (Qiagen) and cDNA
amplified using TaqMan Universal PCR Master Mix or
TaqMan FAST Universal PCR Master Mix with a
StepOnePlus Real Time PCR System (Applied Biosys-
tems). The following Gene Expression Assays (Applied
Biosystems) were used in this study: IP3R1 (Hs00181881_
m1), IP3R2 (Hs00181916_m1), IP3R3 (Hs01573555_m1),
MCU (Hs00293548_m1), NCLX (Hs00227951_m1), RYR1
(Hs00166991_m1), RYR2 (Hs00892840_m1), RYR3 (Hs0
0168821_m1), SERCA1 (Hs01092295_m1), SERCA2 (Hs
00544877_m1), SERCA3 (Hs00193090_m1), SPCA1 (Hs0
0205122_m1), SPCA2 (Hs00208296_m1), Twist (Hs00361
186_m1) and Vimentin (Hs00185584_m1). Relative quan-
tification was calculated with reference to 18S rRNA and
analysed using the comparative CT method [49]. Targets
registering above the limit of detection or having CT values
greater than 35 were assigned a value of 35.
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Measurement of [Ca2+]CYT responses to caffeine was
performed using a fluorometric imaging plate reader
(FLIPRTETRA, Molecular Devices) as previously described
[24]. Briefly, cells were loaded with Fluo-4 AM (2 μM)
in a solution containing PBX Signal Enhancer (5%; PBX
No Wash Ca2+ Assay Kit, BD Biosciences) and probene-
cid (500 μM) in physiological salt solution (KCl 5.9 mM,
MgCl2 1.4 mM, HEPES 10 mM, NaH2PO4 1.2 mM,
NaHCO3 5 mM, NaCl 140 mM, glucose 11.5 mM and
CaCl2 1.8 mM) [6,50]. Calcium measurements were
performed with 470/95 and 515/75 nm excitation and
emission filters. Fluorescent values were normalised to
the point immediately following agonist addition and are
expressed as response over baseline.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
(v6.0 for Windows). Statistical tests used in this study
are outlined in each figure legend.
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